2. Segeberger Kliniken, Herzzentrum, Bad Segeberg, Germany
3. Helios Amper Klinikum, Department of Cardiology and Pneumology, Dachau, Germany
4. Städtische Kliniken Neuss, Lukaskrankenhaus Medizinische Klinik I, Neuss, Germany
5. Hospital Clinic, Cardiology Department, Barcelona, Spain
6. Hospital Universitario Virgen de la Macarena, Hemodynamic Unit, Sevilla, Spain
7. National Institute of Cardiology, Warsaw, Poland
8. Kansai Rosai Hospital Cardiovascular Centre, Japan
9. Sakurakai Takahashi Hospital, Japan
10. MedStar Health Research Institute,Washington DC, USA
11. OLVG Cardiology Unit, Amsterdam, Netherlands
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
To read the full content of this article, please log in to download the PDF.
Methods and results: This prospective, international, multicenter, 2:1 randomized, non-inferiority trial enrolled 575 patients (385 BP-SES and 190 PP-EES) with 659 stenotic de novo lesions. Of these, 137 patients (23.8%) were Japanese. Follow-up until 5 years is ongoing, we herein report outcomes at 12 months. Baseline parameters were well balanced. Device success was 98.9% for BP-SES versus 99.6% for PP-EES, p=0.670. Non-inferiority related to 12-month target vessel failure was met (pnon-inferiority<0.001). Further, there was no significant difference in clinical outcomes between the groups. Target vessel failure rate was 5.5% for BP-SES and 7.5% for PP-EES, target lesion failure rate was 4.2% versus 5.4%, and the definite or probable stent thrombosis rate was 0.8% versus 0%
Conclusions: The randomized BIOFLOW-IV trial provides further evidence on the safety and efficacy of the Orsiro BP-SES and its non-inferiority to the current benchmark, an everolimus-eluting permanent polymer stent.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com